The Pharma Letter5d
FDA approves new use for Pfizer’s Braftovi combo
US pharma giant Pfizer on Friday revealed that the US Food and Drug Administration (FDA) has approved its Braftovi ...
GlobalData on MSN5d
Pfizer’s colorectal cancer combo therapy gains accelerated approval from FDA
The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.
PMLiVE5d
Pfizer’s Braftovi regimen receives FDA accelerated approval to treat colorectal cancer
Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to ...
pharmaphorum4d
FDA approves flurry of drugs ahead of holiday season
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...
Pharmabiz6d
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...
Pharm Exec6d
FDA Grants Accelerated Approval to Pfizer’s Braftovi Combination for Metastatic Colorectal Cancer
The FDA has granted accelerated approval to Pfizer’s Braftovi (encorafenib) in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic colorectal cancer (mCRC) harboring ...
Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked
Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.
Hosted on MSN2d
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...
Businessworld4d
rummy jhil
INR:0189. rummy jhil Scientists discover a pathway that can extend the lifespan of nematodes by 500% CSPC Pharmaceuticals released its financial report for the first t ...